Research & Literature

Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.

Calhoun BC, Collins LC

Seminars in diagnostic pathology 2015; (32(5)):362-9.

Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.

Varga Z, Noske A

PloS one 2015; (10(10)):e0140652 doi:10.1371/journal.pone.0140652.

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Runowicz CD, Leach CR, Henry NL, et al.

CA: a cancer journal for clinicians 2016; (66(1)):43-73 doi:10.3322/caac.21319.

The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature.

Pillay B, Wootten AC, Crowe H, et al.

Cancer treatment reviews 2016; (42()):56-72.

Use of posttreatment imaging and biomarkers in survivors of early-stage breast cancer: Inappropriate surveillance or necessary care?

Hahn EE, Tang T, Lee JS, et al.

Cancer 2016; (122(6)):908-16 doi:10.1002/cncr.29811.

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.

Henry NL, Somerfield MR, Abramson VG, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(19)):2303-11 doi:10.1200/JCO.2015.65.8609.

Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice.

Press MF, Villalobos I, Santiago A, et al.

Archives of pathology & laboratory medicine 2016; (140(11)):1250-1258 doi:10.5858/arpa.2016-0009-OA.

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

Denduluri N, Somerfield MR, Eisen A, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(20)):2416-27 doi:10.1200/JCO.2016.67.0182.

Significance of prognostic indicators in infiltrating duct carcinoma breast: Scenario in developing country.

Krishnamurthy J, Kumar PS

Indian journal of cancer 2016; (53(1)):34-8 doi:10.4103/0019-509X.180834.

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

Press MF, Sauter G, Buyse M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(29)):3518-3528 doi:10.1200/JCO.2016.66.6693.

Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians.

Sisler J, Chaput G, Sussman J, Ozokwelu E

Canadian family physician Medecin de famille canadien 2016; (62(10)):805-811.

HER2-positive breast cancer.

Loibl S, Gianni L

Lancet (London, England) 2017; (389(10087)):2415-2429 doi:10.1016/S0140-6736(16)32417-5.

Predictive model for 5-year mortality after breast cancer surgery in Taiwan residents.

Huang SH, Loh JK, Tsai JT, et al.

Chinese journal of cancer 2017; (36(1)):23 doi:10.1186/s40880-017-0192-9.

Prognostic and predictive biomarkers in breast cancer: Past, present and future.

Nicolini A, Ferrari P, Duffy MJ

Seminars in cancer biology 2018; (52(Pt 1)):56-73 doi:10.1016/j.semcancer.2017.08.010.

Lack of Needs Assessment in Cancer Survivorship Care and Rehabilitation in Hospitals and Primary Care Settings.

Handberg C, Jensen CM, Maribo T

Journal of clinical medicine research 2017; (9(10)):864-871 doi:10.14740/jocmr3160w.

Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.

D'Aloisio AA, Nichols HB, Hodgson ME, et al.

BMC cancer 2017; (17(1)):692 doi:10.1186/s12885-017-3686-6.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Hurvitz SA, Martin M, Symmans WF, et al.

The Lancet. Oncology 2018; (19(1)):115-126 doi:10.1016/S1470-2045(17)30716-7.

Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.

Nowsheen S, Viscuse PV, O'Sullivan CC, et al.

Current breast cancer reports 2017; (9(3)):173-182 doi:10.1007/s12609-017-0249-4.

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.

Larionov AA

Frontiers in oncology 2018; (8()):89 doi:10.3389/fonc.2018.00089.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, et al.

Archives of pathology & laboratory medicine 2018; (142(11)):1364-1382 doi:10.5858/arpa.2018-0902-SA.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(20)):2105-2122 doi:10.1200/JCO.2018.77.8738.

Usefulness of Left Atrial Remodeling in Predicting CardiacToxicity During Trastuzumab Therapy for Breast Cancer.

Bergamini C, Benfari G, Dolci G, et al.

The American journal of cardiology 2018; (122(5)):885-889 doi:10.1016/j.amjcard.2018.05.022.

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Murthy RK, Raghavendra AS, Hess KR, et al.

Clinical breast cancer 2018; (18(6)):e1283-e1288 doi:10.1016/j.clbc.2018.07.008.

New and Important Changes in the TNM Staging System for Breast Cancer.

Hortobagyi GN, Edge SB, Giuliano A

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018; (38()):457-467 doi:10.1200/EDBK_201313.

A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.

Parsons BM, Uprety D, Smith AL, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(11)):1311-1320 doi:10.6004/jnccn.2018.7058.

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

von Minckwitz G, Huang CS, Mano MS, et al.

The New England journal of medicine 2019; (380(7)):617-628 doi:10.1056/NEJMoa1814017.

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.

Lynce F, Barac A, Geng X, et al.

Breast cancer research and treatment 2019; (175(3)):595-603 doi:10.1007/s10549-019-05191-2.

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.

Hurvitz SA, Martin M, Jung KH, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(25)):2206-2216 doi:10.1200/JCO.19.00882.

Breast cancer.

Harbeck N, Penault-Llorca F, Cortes J, et al.

Nature reviews. Disease primers 2019; (5(1)):66 doi:10.1038/s41572-019-0111-2.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Murthy RK, Loi S, Okines A, et al.

The New England journal of medicine 2020; (382(7)):597-609 doi:10.1056/NEJMoa1914609.

Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer-A Randomized Controlled Trial.

Park S, Sato Y, Takita Y, et al.

Journal of pain and symptom management 2020; (60(2)):381-389 doi:10.1016/j.jpainsymman.2020.02.017.

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer.

Wedam S, Fashoyin-Aje L, Gao X, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(16)):4180-4185 doi:10.1158/1078-0432.CCR-19-3980.

The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.

Kreutzfeldt J, Rozeboom B, Dey N, De P

American journal of cancer research 2020; (10(4)):1045-1067.

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.

Lin NU, Borges V, Anders C, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(23)):2610-2619 doi:10.1200/JCO.20.00775.

T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives.

Liu F, Ke J, Song Y

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020; (129()):110407 doi:10.1016/j.biopha.2020.110407.

Effect of multidisciplinary team care on the risk of recurrence in breast cancer patients: A national matched cohort study.

Tsai CH, Hsieh HF, Lai TW, et al.

Breast (Edinburgh, Scotland) 2020; (53()):68-76 doi:10.1016/j.breast.2020.07.001.

Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.

Kunte S, Abraham J, Montero AJ

Cancer 2020; (126(19)):4278-4288 doi:10.1002/cncr.33102.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.

Denduluri N, Somerfield MR, Chavez-MacGregor M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(6)):685-693 doi:10.1200/JCO.20.02510.

Prognostic and predictive parameters in breast pathology: a pathologist's primer.

Allison KH

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2021; (34(Suppl 1)):94-106 doi:10.1038/s41379-020-00704-7.

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.

Thanopoulou E, Khader L, Caira M, et al.

Cancers 2020; (12(11)) doi:10.3390/cancers12113317.

Treatment strategies for breast cancer brain metastases.

Bailleux C, Eberst L, Bachelot T

British journal of cancer 2021; (124(1)):142-155 doi:10.1038/s41416-020-01175-y.

Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa.

Brandão M, Guisseve A, Bata G, et al.

The oncologist 2021; (26(6)):e996-e1008 doi:10.1002/onco.13643.

Germline TP53 Testing in Breast Cancers: Why, When and How?

Evans DG, Woodward ER, Bajalica-Lagercrantz S, et al.

Cancers 2020; (12(12)) doi:10.3390/cancers12123762.

Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review.

Jafari L, Akhter N

Breast cancer research and treatment 2021; (186(2)):295-303 doi:10.1007/s10549-021-06096-9.

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

Korde LA, Somerfield MR, Carey LA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.

Tolaney SM, Tayob N, Dang C, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(21)):2375-2385 doi:10.1200/JCO.20.03398.

Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.

Dempsey N, Rosenthal A, Dabas N, et al.

Breast cancer research and treatment 2021; (188(1)):21-36 doi:10.1007/s10549-021-06280-x.

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

Burstein HJ, Curigliano G, Thürlimann B, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2021; (32(10)):1216-1235 doi:10.1016/j.annonc.2021.06.023.

Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors.

Tran TXM, Jung SY, Lee EG, et al.

Cancer research and treatment 2022; (54(4)):1065-1073 doi:10.4143/crt.2021.835.

How we treat patients with metastatic HER2-positive breast cancer.

Nader-Marta G, Martins-Branco D, de Azambuja E

ESMO open 2022; (7(1)):100343 doi:10.1016/j.esmoop.2021.100343.

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.

Simmons C, Rayson D, Joy AA, et al.

Therapeutic advances in medical oncology 2022; (14()):17588359211066677 doi:10.1177/17588359211066677.

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.

Harbeck N

Breast (Edinburgh, Scotland) 2022; (62 Suppl 1()):S12-S16 doi:10.1016/j.breast.2022.01.006.

Multidisciplinary Management of Breast Cancer and Role of the Patient Navigator.

Fenton A, Downes N, Mendiola A, et al.

Obstetrics and gynecology clinics of North America 2022; (49(1)):167-179 doi:10.1016/j.ogc.2021.11.011.

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.

Swain SM, Nishino M, Lancaster LH, et al.

Cancer treatment reviews 2022; (106()):102378 doi:10.1016/j.ctrv.2022.102378.

Network connectivity between fear of cancer recurrence, anxiety, and depression in breast cancer patients.

Yang Y, Sun H, Luo X, et al.

Journal of affective disorders 2022; (309()):358-367 doi:10.1016/j.jad.2022.04.119.

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem.

Wahdan-Alaswad R, Liu B, Thor AD

Cancer drug resistance (Alhambra, Calif.) 2020; (3(2)):179-198 doi:10.20517/cdr.2019.92.

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.

Giordano SH, Franzoi MAB, Temin S, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(23)):2612-2635 doi:10.1200/JCO.22.00519.

The effect of psychological interventions on fear of cancer recurrence in breast cancer survivors: A systematic review and meta-analysis.

Lyu MM, Siah RC, Lam ASL, Cheng KKF

Journal of advanced nursing 2022; (78(10)):3069-3082 doi:10.1111/jan.15321.

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.

Bartsch R, Berghoff AS, Furtner J, et al.

Nature medicine 2022; (28(9)):1840-1847 doi:10.1038/s41591-022-01935-8.

The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review.

Asgari-Karchekani S, Aryannejad A, Mousavi SA, et al.

Medical oncology (Northwood, London, England) 2022; (39(12)):210 doi:10.1007/s12032-022-01817-6.

Self-Reported Physical Activity, QoL, Cardiac Function, and Cardiorespiratory Fitness in Women With HER2+ Breast Cancer.

Peck SS, Esmaeilzadeh M, Rankin K, et al.

JACC. CardioOncology 2022; (4(3)):387-400 doi:10.1016/j.jaccao.2022.06.006.

Therapeutic landscape of advanced HER2-positive breast cancer in 2022.

Gupta R, Gupta S, Antonios B, et al.

Medical oncology (Northwood, London, England) 2022; (39(12)):258 doi:10.1007/s12032-022-01849-y.

A Vanguard Approach to the Design and Delivery of Nurse-Led Survivorship Care.

Sara SAM, Chambers SK, Briggs R, et al.

Seminars in oncology nursing 2023; (39(1)):151366 doi:10.1016/j.soncn.2022.151366.

The Impact of Tumor Boards on Breast Cancer Care: Evidence from a Systematic Literature Review and Meta-Analysis.

Di Pilla A, Cozzolino MR, Mannocci A, et al.

International journal of environmental research and public health 2022; (19(22)) doi:10.3390/ijerph192214990.

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.

Lin NU, Murthy RK, Abramson V, et al.

JAMA oncology 2023; (9(2)):197-205 doi:10.1001/jamaoncol.2022.5610.

Diastolic heart failure is a new clinical entity of trastuzumab-induced cardiotoxicity: a case report.

Fujita K, Matsumoto K, Kishi A, Kawasaki S

European heart journal. Case reports 2023; (7(1)):ytac470 doi:10.1093/ehjcr/ytac470.

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

de Azambuja E, Agostinetto E, Procter M, et al.

ESMO open 2023; (8(1)):100772 doi:10.1016/j.esmoop.2022.100772.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.

Tolaney SM, Tarantino P, Graham N, et al.

The Lancet. Oncology 2023; (24(3)):273-285 doi:10.1016/S1470-2045(23)00051-7.

Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics.

O'Shaughnessy J, Gradishar W, O'Regan R, Gadi V

Clinical breast cancer 2023; (23(4)):350-362 doi:10.1016/j.clbc.2023.03.007.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.

Wolff AC, Somerfield MR, Dowsett M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(22)):3867-3872 doi:10.1200/JCO.22.02864.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.

Wolff AC, Somerfield MR, Dowsett M, et al.

Archives of pathology & laboratory medicine 2023; (147(9)):993-1000 doi:10.5858/arpa.2023-0950-SA.

Can You Establish the Cause of This Patient's Shortness of Breath?

Trail A, Rogers J, Ajani J

Journal of the advanced practitioner in oncology 2023; (14(5)):440-443 doi:10.6004/jadpro.2023.14.5.8.

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective.

Henning JW, Brezden-Masley C, Gelmon K, et al.

Current oncology (Toronto, Ont.) 2023; (30(9)):8019-8038 doi:10.3390/curroncol30090582.

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).

Niikura N, Yamanaka T, Nomura H, et al.

NPJ breast cancer 2023; (9(1)):82 doi:10.1038/s41523-023-00584-5.

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report.

de Weger VA, Schutte T, Konings IRHM, Menke-van der Houven van Oordt CW

Journal of breast cancer 2023; (26(5)):519-523 doi:10.4048/jbc.2023.26.e38.

Clinicopathologic Features of 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 Breast Carcinoma (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0).

Wilcock D, Sirohi D, Albertson D, et al.

Archives of pathology & laboratory medicine 2024; (148(8)):890-897 doi:10.5858/arpa.2023-0275-OA.

Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations.

Hart NH, Nekhlyudov L, Smith TJ, et al.

JCO oncology practice 2024; (20(9)):1160-1172 doi:10.1200/OP.23.00716.

A Comprehensive Review of HER2 in Cancer Biology and Therapeutics.

Cheng X

Genes 2024; (15(7)) doi:10.3390/genes15070903.

Role of Radiology in the Diagnosis and Treatment of Breast Cancer in Women: A Comprehensive Review.

Arslan M, Asim M, Sattar H, et al.

Cureus 2024; (16(9)):e70097 doi:10.7759/cureus.70097.

Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer.

Bartsch R, Cameron D, Ciruelos E, et al.

Cancer treatment reviews 2025; (132()):102853 doi:10.1016/j.ctrv.2024.102853.

Scanxiety and Fear of Recurrence in Young Adult Female Breast and Gynaecological Cancer Survivors: Investigating Shared Mechanisms.

Patel DS, Webster SN, Dowling EJ, et al.

Psycho-oncology 2024; (33(12)):e70050 doi:10.1002/pon.70050.

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

Geyer CE, Untch M, Huang CS, et al.

The New England journal of medicine 2025; (392(3)):249-257 doi:10.1056/NEJMoa2406070.

Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan.

Williamson J, Kelley K, Scholand MB, et al.

Breast cancer research and treatment 2025; (210(2)):487-491 doi:10.1007/s10549-024-07586-2.

Association of Surgeon Volume with Adherence to American Society of Breast Surgeons Surgical Quality Measures.

Chan K, Palis BE, Cotler JH, et al.

Annals of surgical oncology 2025; (32(11)):8144-8155 doi:10.1245/s10434-025-17846-0.

Cardiac function surveillance practices and outcomes in patients with HER2-positive breast cancer treated with trastuzumab: a retrospective cohort study across a safety-net and tertiary care setting.

Huang L, Manthena P, Su M, et al.

Cardio-oncology (London, England) 2025; (11(1)):74 doi:10.1186/s40959-025-00376-9.

MRI-Based Assessment of Margin Status Determinants, Preoperative Predictors, and Prognostic Outcomes in Breast-Conserving Surgery Following Neoadjuvant Therapy.

Liu X, Liu Y, Ma T, et al.

World journal of surgery 2025; (49(10)):2620-2629 doi:10.1002/wjs.70072.

Trastuzumab Deruxtecan-Associated Interstitial Lung Disease: Real-World Insights from a Tertiary Care Center.

Alanazi AS, Alanazi AA, Alanizi A, et al.

Current oncology (Toronto, Ont.) 2025; (32(10)) doi:10.3390/curroncol32100575.

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

Tolaney SM, Jiang Z, Zhang Q, et al.

The New England journal of medicine 2026; (394(6)):551-562 doi:10.1056/NEJMoa2508668.

Expert consensus on disease-based long-term follow-up care plans for childhood cancer survivors.

Cai JY, Pui CH, Ju XL, et al.

World journal of pediatrics : WJP 2025; (21(12)):1204-1217 doi:10.1007/s12519-025-00989-1.

Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer.

Shang A, Xiong Y, Li M, et al.

Technology in cancer research & treatment 2026; (25()):15330338261446455 doi:10.1177/15330338261446455.

Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review.

Santos Nussbaum ACA, Antonini M, Mattar A, et al.

Cardio-oncology (London, England) 2026; (12(1)).

Breast Cancer Multi-Disciplinary Team Meetings in a Resource-Constrained System: Are Patients Receiving the Treatment Recommended?

Naidoo N, Martin L, Conradie W, et al.

World journal of surgery 2026; (50(6)):1481-1486 doi:10.1002/wjs.70405.

Chinese Society of Clinical Oncology breast cancer expert consensus on the diagnosis and treatment of breast cancer brain metastasis (2025).

Wang T, Chen J, Yang J, et al.

Translational breast cancer research : a journal focusing on translational research in breast cancer 2026; (7()):20 doi:10.21037/tbcr-25-51.

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Nahleh Z, Alfano CM, Somerfield MR, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; JCO2601700 doi:10.1200/JCO-26-01700.

Interstitial lung disease in patients treated with antibody-drug conjugates: a review.

Petrelli F, Dottorini L, D'Alessio A, et al.

Lung cancer (Amsterdam, Netherlands) 2026; (219()):109532 doi:10.1016/j.lungcan.2026.109532.

Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review.

Sakai H, Tsurutani J

Translational breast cancer research : a journal focusing on translational research in breast cancer 2026; (7()):28 doi:10.21037/tbcr-25-29.

Real-World Cardiotoxicity of Biosimilar versus Reference Trastuzumab in Early HER2-Positive Breast Cancer.

Jackson I, Zhang N, Sullivan M, et al.

JACC. CardioOncology 2026; doi:10.1016/j.jaccao.2026.07.009.